Entia Biosciences (ERGO) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 10, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Entia Biosciences, Inc.	'
Entity Central Index Key	'0001408299	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	8,437,345
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash	$85,608	$36,886
Accounts receivable, net	65,662	11,197
Inventory, net	116,778	138,941
Interest income receivable	0	3,965
Prepaid expenses	19,100	34,462
Total Current Assets	287,148	225,451
Property and Equipment, net	48,583	62,145
Patents and license, net	333,677	343,498
Total Assets	669,408	631,094
Current Liabilities:	'	'
Accounts payable and accrued expenses	557,982	1,157,717
Short-term convertible notes payable, net of discount related-party	15,000	23,427
Short-term convertible notes payable, net of discount	634,548	373,644
Capital lease payable	0	2,105
Notes payable	29,764	23,788
Total Current Liabilities	1,237,294	1,580,681
Total Liabilities	1,237,294	1,580,681
Stockholders' Equity (Deficit):	'	'
Preferred stock, $.001 par value, 5,000,000 shares authorized, Series A preferred stock, 350,000 shares designated, 207,807 and 281,969 shares issued and outstanding, resepecively, aggregate liquidation value of $1,039,035 and $1,409,845 respectively	208	282
Common stock, $.001 par value, 150,000,000 shares authorized, 13,204,359 and 8,297,645 shares issued and outstanding	13,205	8,298
Stock subscription receivable	0	-49,000
Additional paid-in capital	9,652,344	7,793,760
Deferred compensation	-108,799	-182,576
Accumulated deficit	-10,124,844	-8,520,351
Total Stockholders' Equity (Deficit)	-567,886	-949,587
Total Liabilities and Stockholders' Equity (Deficit)	$669,408	$631,094

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred Stock	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock Series A, designated	350,000	350,000
Preferred stock, issued	207,807	281,969
Preferred stock, aggregate liquidation value	$1,039,035	$1,409,845
Common Stock	'	'
Common Stock, par value	$0.00	$0.00
Common stock, authorized	150,000,000	150,000,000
Common stock, Issued	13,204,359	8,297,645

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
REVENUES	$87,753	$92,102	$355,014	$262,245
COST OF GOODS SOLD	40,059	33,560	136,083	91,547
GROSS PROFIT	47,694	58,542	218,931	170,698
OPERATING EXPENSES	'	'	'	'
Advertising and promotion	42,368	23,399	77,454	151,672
Professional fees	36,166	38,493	123,382	115,731
Consulting fees	21,440	79,365	315,032	608,104
Impairment of intangible asset	27,080	0	27,080	0
General and administrative	334,358	396,337	1,051,506	1,202,148
Total Operating Expenses	461,412	537,594	1,594,454	2,077,655
LOSS FROM OPERATIONS	-413,718	-479,052	-1,375,523	-1,906,957
OTHER INCOME (EXPENSES)	'	'	'	'
Interest income	0	2,512	0	7,412
Interest expense	-82,123	-34,188	-256,525	-101,790
Other income (expense)	37,499	0	24,534	0
Loss on write-off of debt discount	-100,000	0	-100,000	0
Gain on settlement of accounts payable	0	0	103,021	0
NET LOSS	-558,342	-510,728	-1,604,493	-2,001,335
DEEMED DIVIDEND RELATED TO BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE PREFERRED STOCK	$0	($39,800)	$0	($39,800)
NET LOSS PER SHARE ALLOCABLE TO COMMON STOCKHOLDERS	($558,342)	($550,528)	($1,604,493)	($2,041,135)
NET LOSS PER COMMON SHARE	'	'	'	'
- BASIC AND DILUTED:	$ (0.06)	($0.07)	($0.18)	($0.28)
Weighted common shares outstanding	'	'	'	'
- basic and diluted	10,091,052	7,712,950	8,986,310	7,395,137

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Preferred Stock	Common Stock	Additional Paid In Capital	Deferred Compensation	Stock Subscriptions	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$110	$7,444	$5,115,587	($394,510)	($49,000)	($5,327,924)	($648,293)
Beginning Balance, Shares at Dec. 31, 2012	109,900	7,444,591	'	'	'	'	'
Issuance of preferred stock for cash, Shares	140,175	'	'	'	'	'	'
Issuance of preferred stock for cash, Amount	140	'	700,735	'	'	'	700,875
Issuance of preferred stock for cancellation of debt, Shares	3,162	'	'	'	'	'	'
Issuance of preferred stock for cancellation of debt, Amount	3	'	15,747	'	'	'	15,750
Deemed dividend related to beneficial conversion feature of convertible preferred stock, Shares	'	'	87,600	'	'	'	-87,600
Issuance of preferred stock for conversion of convertible notes payable, Shares	23,332	'	'	'	'	'	'
Issuance of preferred stock for conversion of convertible notes payable, Amount	23	'	116,629	'	'	'	116,652
Issuance of preferred stock for conversion of accounts payable, Shares	30,400	'	'	'	'	'	'
Issuance of preferred stock for conversion of accounts payable, Amount	31	'	151,970	'	'	'	152,001
Issuance of warrants in connection with convertible notes payable	'	'	16,400	'	'	'	16,400
Beneficial conversion feature in connection with convertible notes payable	'	'	64,956	'	'	'	64,956
Issuance of common stock for license agreement, Shares	'	200,000	'	'	'	'	'
Issuance of common stock for license agreement, Amount	'	200	215,329	'	'	'	215,529
Issuance of common stock for conversion of preferred stock, Shares	-25,000	250,000	'	'	'	'	'
Issuance of common stock for conversion of preferred stock, Amount	-25	250	-225	'	'	'	'
Issuance of common stock for conversion of accrued compensation, Shares	'	273,158	'	'	'	'	'
Issuance of common stock for conversion of accrued compensation, Amount	'	274	129,727	'	'	'	130,001
Issuance of common stock for services, Shares	'	129,896	'	'	'	'	'
Issuance of common stock for services, Amount	'	130	83,270	'	'	'	'
Issuance of common stock and warrants for cash, Shares	'	'	'	'	'	'	4,607,050
Stock compensation, Amount	'	'	413,921	'	'	'	413,921
Issuance of warrants for services	'	'	584,108	-584,108	'	'	'
Issuance of warrants for extension on debt	'	'	98,006	'	'	'	98,006
Amortization of deferred compensation	'	'	'	796,042	'	'	796,042
Net loss	'	'	'	'	'	-3,104,827	-3,104,827
Ending Balance, amount at Dec. 31, 2013	282	8,298	7,793,760	-182,576	-49,000	-8,520,351	-949,587
Ending Balance, shares at Dec. 31, 2013	281,969	8,297,645	'	'	'	'	'
Issuance of warrants in connection with convertible notes payable	'	'	68,735	'	'	'	68,735
Beneficial conversion feature in connection with convertible notes payable	'	'	146,637	'	'	'	146,637
Issuance of common stock for conversion of preferred stock, Shares	-71,162	741,620	'	'	'	'	'
Issuance of common stock for conversion of preferred stock, Amount	-74	742	-668	0	0	0	0
Issuance of common stock for conversion of convertible debt, Shares	'	1,197,011	'	'	'	'	'
Issuance of common stock for conversion of convertible debt, Amount	'	1,197	308,523	0	0	0	309,720
Issuance of common stock for conversion of accounts payable, Shares	'	94,530	'	'	'	'	'
Issuance of common stock for conversion of accounts payable, Amount	'	95	55,806	0	0	0	55,901
Issuance of common stock for future services, Shares	'	68,283	'	'	'	'	'
Issuance of common stock for future services, Amount	'	68	44,182	-44,250	'	'	'
Issuance of common stock for services, Shares	'	212,700	'	'	'	'	'
Issuance of common stock for services, Amount	'	213	107,669	'	'	'	107,882
Stock compensation, Amount	'	'	143,549	'	'	'	143,549
Receipt of stock subcription receivable, less write-off of $9,000	'	'	'	'	49,000	'	49,000
Issuance of warrants for conversion of accrued salary	'	'	91,863	'	'	'	91,863
Issuance of warrants for services	'	'	117,110	-117,110	'	'	'
Amortization of deferred compensation	'	'	'	235,137	'	'	235,137
Net loss	'	'	'	'	'	-1,604,493	-1,604,493
Ending Balance, amount at Sep. 30, 2014	$208	$13,205	$9,652,344	($108,799)	$0	($10,124,844)	($567,886)
Ending Balance, shares at Sep. 30, 2014	207,807	13,204,359	'	'	'	'	'

CONSOLIDATED_STATEMENT_OF_STOC1

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	9 Months Ended
	Sep. 30, 2014
Statement of Stockholders' Equity [Abstract]	'
Write off amount on stock subscription receivable	$9,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,604,493)	($2,001,335)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation/amortization	56,318	25,104
Gain on settlement of accounts payable	-103,021	0
Impairment of intangible asset	27,080	0
Loss on write-off of debt discount	100,000	0
Amortization of discount on convertible notes	221,548	78,142
Stock-based compensation	486,568	875,343
Loss on sale of stock subscription receivable	12,965	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	-54,465	-30,867
Inventory	22,163	3,714
Prepaid expenses	28,275	19,027
Other current assets	0	-512
Accounts payable and accrued expenses	404,761	541,569
NET CASH USED IN OPERATING ACTIVITIES	-402,301	-489,815
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of property and equipment	-4,607	-55,448
Acquisition of patents and patents pending (net)	-28,328	-20,044
NET CASH USED IN INVESTING ACTIVITIES	-32,935	-75,492
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock, preferred stock and warrants	0	565,865
Proceeds from convertible notes payable short-term	503,000	50,000
Payment on notes payable	-34,042	-18,284
Payment on convertible note payable - related party	-40,000	0
Proceeds from sale of stock subscription receivable	40,000	0
Proceeds from convertible note payable-related party	15,000	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	483,958	597,581
NET CHANGE IN CASH	48,722	32,274
Cash at beginning of period	36,886	13,081
Cash at end of period	85,608	45,355
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:	'	'
Interest paid	843	906
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:	'	'
Stock issued for accounts payable	55,901	0
Conversion of accounts payable, accrued compensation, notes payable and accrued interest to preferred and common stock	1,087,490	414,404
Issuance of warrants for accrued salary	91,863	0
Debt issued for license	0	140,000
Common stock issued for future services	'	'

NOTE_1_ORGANIZATION_AND_OPERAT

NOTE 1 - ORGANIZATION AND OPERATIONS	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
NOTE 1 - ORGANIZATION AND OPERATIONS	'
	NOTE 1 – ORGANIZATION AND OPERATIONS
	Generic Marketing Services, Inc. was incorporated on July 19, 2007 under the laws of the State of Nevada as a subsidiary of Basic Services, Inc., also a Nevada corporation. On December 31, 2007, Basic Services spun off Generic Marketing Services. On October 8, 2008, Generic Marketing Services changed its name to Total Nutraceutical Solutions, Inc. (TNS, the Company, us, we, or our). We engage in the distribution of organic dietary supplement nutraceutical products in the United States of America. We are also engaged in the discovery, scientific evaluation and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics and other products developed and sold by Entia and by third parties.
	On January 9, 2012, the amendment to our Articles of Incorporation involving the name change from Total Nutraceutical Solutions, Inc. to Entia Biosciences, Inc. (“Entia”) became effective with the Secretary of State of Nevada. We also filed articles of incorporation for a wholly owned subsidiary of Entia, with such subsidiary to be named Total Nutraceutical Solutions, Inc. in January 2012.
	We have a history of incurring net losses and net operating cash flow deficits. We are also developing new technologies related to our organic nutraceutical products. At June 30, 2014, we had cash and cash equivalents of $85,608. These conditions raise substantial doubt about our ability to continue as a going concern. As a result, we anticipate that our cash and cash equivalent balances, anticipated cash flows from operations and anticipated operating cash flows will be sufficient to meet our cash requirements through December 2014.
	In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. The issuance of equity securities will also cause dilution to our shareholders. If external financing sources of financing are not available or are inadequate to fund our operations, we will be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans. The accompanying consolidated financial statements have been prepared assuming that the Company continues as a going concern.
	The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

NOTE_2_SUMMARY_OF_SIGNIFICANT_

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation and principles of consolidation
	The accompanying consolidated unaudited interim financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC.
	All intercompany accounts have been eliminated for the purpose of the consolidated financial statement presentation.
	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash
	We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
	Accounts receivable
	Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We consider all accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $2,526 at both September 30, 2014 and December 31, 2013.
	Inventory
	Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the first-in, first-out method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.
	Property and equipment
	Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Office equipment		3 years
	Production equipment		5 to 7 years
	Equipment under capital lease		5 to 7 years
	Leasehold improvements		Lesser of lease term or useful life of improvement
	Patents
	Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
	Impairment of long-lived assets
	Our long-lived assets, which include property and equipment, patents and licenses of patents, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. There was an impairment on patents recorded for the third quarter ended September 30, 2014, amounting to $27,080.
	Discount on convertible notes payable
	We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statements of operations.
	Fair value of financial instruments
	The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable, approximate their fair values (determined based on level 1 inputs in the fair value hierarchy) because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
	Fair value measurements
	We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3		Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at September 30, 2014 or December 31, 2013, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the periods ended September 30, 2014 and September 30, 2013.
	Revenue recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.
	Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.
	Shipping and handling costs
	Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred.
	Advertising and promotion costs
	Costs associated with the advertising and promotions of our products are expensed as incurred.
	Equity instruments issued to parties other than employees for acquiring goods or services
	We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock.
	The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.
	The assumptions used to determine the fair value of our warrants are as follows:
	-	The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.
	-	The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant.
	-	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.
	-	The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.
	Income taxes
	We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.
	We did not record an income tax provision for the three months and nine months ended September 30, 2014 and 2013 as we had a net taxable loss in the periods.
	Net loss per common share
	Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for three months ended September 30, 2014 and 2013 and the nine months ended September 30, 2014 and 2013. The following table presents a reconciliation of basic loss per share and excluded dilutive securities:
				For the Three Months Ended September 30,		For the Nine Months Ended September 30,
				2014	2013	2014	2013
	Numerator:
	Net loss			($558,342)	($550,528)	($1,604,493)	($2,041,135)
	Denominator:
	Weighted-average common shares outstanding			10,091,052	7,712,950	8,986,310	7,395,137
	Basic and diluted net loss per share			($0.06)	($0.07)	($0.18)	($0.28)
	Common stock warrants			5,019,006	3,987,744	5,019,006	3,987,744
	Series A convertible preferred stock			2,078,070	2,699,690	2,078,070	2,699,690
Stock options			2,848,670	1,651,118	2,848,670	1,651,118
Convertible debt including interest			915,085	856,030	915,085	856,030
Excluded dilutive securities			10,860,831	9,194,582	10,860,831	9,194,582
Reclassifications
Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segments
We have determined that we operate in one segment for financial reporting purposes.
Recently issued accounting pronouncements
In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements.

NOTE_3_INVENTORY

NOTE 3 - INVENTORY	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
NOTE 3 - INVENTORY	'
	NOTE 3 – INVENTORY
	Inventory consists of the following:
		September 30,	December 31,
		2014	2013
	Raw materials	$ 217,430	$ 240,750
	Finished goods	50,412	49,255
		267,842	290,005
	Less:  reserve for excess and obsolete inventory	-151,064	-151,064
		$ 116,778	$ 138,941

NOTE_4_PROPERTY_AND_EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
NOTE 4 - PROPERTY AND EQUIPMENT	'
	NOTE 4 – PROPERTY AND EQUIPMENT
	Property and equipment, stated at cost, consists of the following:
		September 30,	December 31,
		2014	2013
	Office equipment	$ 27,507	$ 26,284
	Production equipment	86,999	83,615
	Leasehold improvements	16,328	16,328
		130,34	126,227
	Less:  accumulated depreciation	-82,251	-64,082
		$ 84,583	$ 62,145

NOTE_5_PATENTS_AND_LICENSES_NE

NOTE 5 - PATENTS AND LICENSES, NET	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 5 - PATENTS AND LICENSES, NET	'
	NOTE 5 - PATENTS AND LICENSES, NET
	Our identifiable long-lived intangible assets are patents and prepaid licenses. Patent and license amortization is $3,371 and $3,578 for the three months ended September 30, 2014 and 2013, respectively and $11,070 and $6,824 for the nine months ended September 30, 2014 and 2013, respectively.
	The licenses are being amortized over an economic useful life of 17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at:
		September 30,	December 31,
		2014	2013
	Licenses and amortizable patents	$ 207,244	$ 234,324
	Unamortized patents	153,630	125,301
	Accumulated amortization	-27,197	-16,127
	Patents and Licenses, net	$ 333,677	$ 343,498
	During third quarter 2014, we recorded an impairment on one of our patents and expensed this amount. The amount expensed is $27,080 and is recorded as an impairment to intangibles on our consolidated statements of operations.

NOTE_6_ACCRUED_EXPENSES

NOTE 6 - ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
NOTE 6 - ACCRUED EXPENSES	'
	NOTE 6 – ACCRUED EXPENSES
	Accrued expenses (included with accounts payable) consists of the following at:
		September 30,	December 31,
		2014	2013
	Executive compensation	$30,197	$476,368
	Other accruals	19,575	60,671
		$49,772	$537,039
	During third quarter, 2014, we negotiated agreements with our employees to accept either warrants or shares of common stock for conversion of their accrued payroll. The conversion rate for the warrants or common stock would be at $0.30 per share. During third quarter, we issued 2,592,570 shares of common stock to our key employees for conversion of $777,770 of accrued compensation. In addition, we granted 10 year warrants to purchase 306,208 of common stock exercisable at $0.0001 per share. These warrants fully vested on date of grant and had a grant date fair value of $91,863.

NOTE_7_NOTES_PAYABLE

NOTE 7 - NOTES PAYABLE	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
NOTE 7 - NOTES PAYABLE	'
	NOTE 7 – NOTES PAYABLE
	Notes payable consists of the following:
				September 30,	December 31,
				2014	2013
	Notes payable - current
	7.85% unsecured, $781 due monthly			$3,659	$1,964
	7.85% unsecured, $373 due monthly			1,105	-
	4.15% unsecured, $2,678 due monthly			-	21,824
	10.00% unsecured, interest only, due December 30, 2014			25,000	-
				$29,764	$23,788
	Convertible notes payable, net			September 30,	31-Dec-13
				2014
	8%, unsecured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share.			$312,500	$263,496
	8% secured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share.			50,000	37,700
	6% unsecured, convertible into common stock at $2.00 per share, due on demand			50,000	50,000
	8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $40,552 in 2013), convertible into common stock at an average price of $0.205 per share  This note was converted during August 2014.			-	22,448
	8% unsecured due November 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after September 2, 2014.  This note was converted during August 2014.			-	-
	8% unsecured due January 2015 (net of discount related to beneficial conversion feature of $9,152 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after October 17, 2014.			23,348	-
	8% unsecured due March 2015 (net of discount related to beneficial conversion feature of $14,382 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after December 13, 2014.			18,118	-
	10% unsecured due March 2015 (net of discount related to warrants of $4,725 in 2014 and $0 in 2013) convertible price not yet determined			20,275	-
	10% unsecured due April 2015 (net of discount related to warrants of $19,600 in 2014 and $0 in 2013) convertible price not yet determined			80,400	-
	10% unsecured due April 2015 (net of discount related to warrants of $2,409 in 2014 and $0 in 2013) convertible price not yet determined			7,591	-
	8% unsecured due April 2015 (net of discount related to beneficial conversion feature of $22,227 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after January 14, 2015.			20,273	-
	8% unsecured due May 2015 (net of discount related to beneficial conversion feature of $31,983 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after February 11, 2015.			21,017	-
	10% unsecured due August 2015 (net of discount related to warrants of $6,600 in 2014 and $0 in 2013) convertible price not yet determined			23,400	-
	10% unsecured due September 2015 (net of discount related to warrants of $2,374 in 2014 and $0 in 2013) convertible price not yet determined			7,626	-
				$634,548	$373,644
	Convertible notes payable, net related party			30-Sep-14	31-Dec-14
	0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share.  This note was paid off on March 31, 2014.			$ -	$23,427
	0% unsecured due October 1, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $0 in 2013 convertible into common stock at $0.50 per share.  Subsequent to September 30, 2014, we reached an agreement with the note holder to extend the maturity date.  See Note 11 for further details.			$15,000	$ -
				$15,000	$23,427
	$312,500 in notes payable was due on June 30, 2014. We are currently in negotiations with the note holder to extend this note and we are not in default.
	$50,000 in notes payable was due during August, 2014. We are currently in negotiations with the note holder to extend this note and we are not in default.
	During first quarter 2014, we entered into a promissory note for $25,000 at 10% interest due on December 30, 2014. This note is not convertible and is listed with notes payable as a short-term liability on the balance sheet.
	On August 28, 2014, we entered into a convertible promissory note for $100,000. The note was convertible into common stock at $0.25 per share. The investor converted the notes right away and received 400,000 shares of common stock. Following the conversion, we wrote off the debt discount for a loss of $100,000. We have recorded this as an expense on our consolidated statements of operations.
	During 2014, we entered into the following debenture agreements that accrue interest at 10%, mature in 1 year and grant the investor on a one warrant per dollar basis that are exercisable for 3 years at $1 per share and vest immediately:
		o	On September 2, 2014, we entered into an agreement for $10,000. We calculated the fair value of the warrants at $2,590.
		o	On August 28, 2014, we entered into an agreement for $30,000. We calculated the fair value of the warrants at $7,290.
		o	On April 15, 2014, we entered into an agreement for $10,000. We calculated the fair value of the warrants at $4,130,
		o	On April 27, 2014, we entered into an agreement for $100,000. We calculated the fair value of the warrants at $39,200, and
		o	On March 28, 2014, we entered into an agreement for $25,000. We calculated the fair value of the warrants at $9,450.
	We posted the fair value of the warrants as a discount on the notes and amortize them over the life of the debenture.
	In addition to the debentures, during 2014, we entered into the following convertible promissory notes with an interest rate of 8% per annum, compounded annually. If the note remains unpaid after one hundred eighty (180) days from the Issue date, the holder has the option to convert the principal and accrued interest into shares of our Company stock at a conversion price equal to 58% of the “trading price” as described in the note. We have calculated a discount for the beneficial conversion feature and will be amortized over the life of the loan.
		o	On February 3, 2014, $42,500 due on November 3, 2014,
		o	On April 17, 2014, $32,500 due on January 17, 2015,
		o	On June 13, 2014, $32,500 due on March 13, 2015,
		o	On July 14, 2014, $42,500 due on April 13, 2015, and
		o	On August 11, 2014, $53,000 due on May 10, 2015.
	On March 25, 2014, we entered into a line of credit arrangement. The line of credit is $60,000 with an interest rate of prime plus 3.00%. There are no loan covenants applicable to this line of credit and the amount outstanding as of September 30, 2014 is $0.

NOTE_8_RELATED_PARTY_TRANSACTI

NOTE 8 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
NOTE 8 - RELATED PARTY TRANSACTIONS	'
	NOTE 8 – RELATED PARTY TRANSACTIONS
	Debt agreements from board member
	In December 2013, we entered into a promissory note due on March 31, 2014 at 0% in the principal amount of $40,000 with Dr. Philip Sobol, a member of our board of directors. The note was paid off on March 31, 2014.
	On July 1, 2014, we entered into a promissory note due on October 31, 2014 at 0% in the principal amount of $15,000 with Dr. Philip Sobol, a member of our board of directors. In conjunction with the note, we granted Dr. Sobol a five year warrant to purchase 15,000 shares of common stock at $0.50 per share and fully vests upon receipt of monies. We calculated a discount on the granting of the warrants in the amount of $5,445 and expensed this during the third quarter to interest expense. The note also contained a conversion feature where Dr. Sobol can convert the note into common stock at $0.50 per share. We calculated and posted a discount related to this conversion feature of $7,545 and amortized it during the third quarter 2014.

NOTE_9_STOCKHOLDERS_EQUITY_DEF

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT)	'
	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)
	Preferred Stock
	On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value. The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and is currently convertible into common stock on a one-for-ten basis.
	During third quarter 2014, two investors converted 30,000 shares of Series A Preferred stock for 300,000 shares of common stock.
	During second quarter 2014, two investors converted 44,162 shares of Series A Preferred stock for 441,620 shares of common stock.
	Common stock
	During third quarter 2014, we issued shares of common stock for the following:
		o	645,885 shares of common stock with a value of $77,200 upon conversion of $75,500 of convertible notes payable along with accrued interest of $1,700.
		o	300,000 shares of common stock in exchange for 30,000 shares of Series A Preferred stock,
		o	2,592,570 shares of common stock in exchange for converting $777,770 of accrued salary to two key employees,
		o	400,000 shares of common stock with a value of $107,882 in exchange for conversion of notes payable,
		o	7,813 shares of common stock with a value of $5,000 for the settlement of accounts payable.
		o	50,000 shares of common stock in conjunction with a distributor agreement valued at $21,500. This amount is posted as a reduction in revenues, and
		o	75,000 shares of common stock with a value of $33,713 for services rendered.
	During second quarter 2014, we issued shares of common stock for the following:
		o	151,126 shares of common stock with a value of $32,520 upon conversion of $30,000 of convertible notes payable along with accrued interest of $2,520,
		o	23,000 shares of common stock for a value of $13,113 for services rendered,
		o	441,620 shares of common stock in exchange for 44,162 shares of Series A Preferred stock, and
		o	80,000 shares of common stock with a value of $46,400 for the settlement of accounts payable in the amount of $149,421. We posted a gain on settlement in the amount of $103,021.
	During first quarter 2014, we issued shares of common stock for the following:
		o	64,700 shares of common stock for a value of $39,556 for services rendered,
		o	68,283 shares of common stock for a value of $44,250 for services to be performed in the future, and
		o	6,717 shares of common stock with a value of $4,501 for the settlement of accounts payable.
	Stock incentive plan
	On September 17, 2010, our Board of Directors adopted the 2010 Stock Incentive Plan (“Plan”). The Plan provides for the grant of options to purchase shares of our common stock, and stock awards consisting of shares of our common stock, to eligible participants, including directors, executive officers, employees and consultants of the Company. We have reserved 4,650,000 shares of common stock for issuance under the Plan with an annual increase in shares of 50,000 as of January 1 of each year; commencing January 1, 2012. Stock options are granted at or below the closing price of our stock on the date of grant for terms ranging from four to fifteen years and generally vest over a five year period. The fair value of option grants were calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions:
			September 30,	December 31,
			2014	2013
	Expected dividend yield		-	-
	Expected stock price volatility		182.94%-216.96%	216.96% - 236.55%
	Risk-free interest rate		0.28% - 1.91%	0.95% - 2.47%
	Expected term (in years)		3 - 7 years	5 - 10 years
	Weighted-average granted date fair value		$0.48	$0.45
	A summary of option activity under the stock option plan as of September 30, 2014 and changes during the quarter then ended is presented below:
						Weighted
						Average
					Weighted	Remaining
			Number of	Exercise Price	Average Exercise	Contractual Term	Aggregate Intrinsic
			Shares	Range	Price	(Years)	Value
	Outstanding, December 31, 2012		1,202,099	$ 0.40-$1.00	$0.56	7.74	-
	Exercisable, December 31, 2012		830,504	$ 0.40-$1.00	$0.57	8.19	-
	Granted		1,150,000	$ 0.38-$0.81	$0.47	8.07	-
	Exercised		-	-	$ -	-	-
	Expired		-	-	$ -	-	-
	Outstanding, December 31, 2013		2,352,099	$ 0.38-$1.00	$0.51	7.9	199,505
	Exercisable, December 31, 2013		1,810,344	$ 0.38-$1.00	$0.52	7.88	138,707
	Granted		496,571	$ 0.40-$0.75	$0.48	6.36
	Exercised		-	-	$ -	-
	Expired		-	-	$ -	-
	Outstanding, September 30, 2014		2,848,670	$ 0.38-$1.00	$0.52	7.68	-
	Exercisable, September 30, 2014		2,125,502	$ 0.38-$1.00	$0.49	9.13	-
	The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at September 30, 2014 are as follows:
	Number of		Exercise
	shares		Price
	55,000		$0.38
	1,286,670		$0.40
	30,000		$0.42
	20,000		$0.44
	190,000		$0.45
	824,000		$0.50
	160,000		$0.60
	15,000		$0.62
	20,000		$0.75
	10,000		$0.81
200,000		$0.85
38,000		$1.00
2,848,670
At September 30, 2014, the Company had 1,801,330 unissued shares available under the Plan. Also, at September 30, 2014, the Company had $228,697 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 7 years.
Warrants – Consulting Agreements
Outstanding warrants to purchase common stock are as follows:
Date of Issue		30-Sep-14	Exercise Price	Expiration
14-Sep		316,208	$0.00	Sep-24
14-Aug		80,000	$0.50 - $1.00	8/2017 - 8/2019
14-Jun		15,000	$0.50	Jun-19
14-Apr		113,333	$0.65 - 1.00	04/2017 - 03/2021
14-Jan		62,277	$0.65 - $1.00	01/2019 - 01/2021
As of December		4,457,188	$0.36 - $10.00	10/2014 - 10/2021
2013
Total		5,044,006
Less:
Expired		25,000
Exercised		-
Total		5,019,006
We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant. In determining the fair value of warrants, we employed the following key assumptions:
		30-Sep-14	31-Dec-13
Risk-Free interest rate		0.28% - 2.97%	0.95% - 3.32%
Expected dividend yield		0%	0%
Volatility		182.81%-222.30%	216.48%-239.20%
Expected life		3 - 7 years	3-10 years
At September 30, 2014 and 2013, the weighted-average Black-Scholes value of warrants granted was $0.66 and $1.52, respectively.

NOTE_10_COMMITMENTS_AND_CONTIN

NOTE 10 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
NOTE 10 - COMMITMENTS AND CONTINGENCIES	'
	NOTE 10 - COMMITMENTS AND CONTINGENCIES
	Leases
	On April 4, 2012, the Company entered into a Commercial Lease agreement with Lanz Properties, LLC for 13,081 square feet of office and warehouse space located at 13565 SW Tualatin-Sherwood Road, Suite 800, Sherwood, OR 97140. The new lease commenced on June 1, 2012 and will terminate on July 31, 2015. No rent was payable until October 2012. The base monthly rental rate started at $3,160, increasing to $3,260 in October 2013, and then $3,343 in June 2014. The Company has straight-lined the full value of the lease agreement over the life of the lease and has recorded this amount monthly. The amount of rent expense that is above the actual rent amount is recorded as deferred rent and is shown on the balance sheet in current liabilities as part of accounts payable and accrued expenses. The amount recorded for as of September 30, 2014 and 2013 is $2,719 and $18,782, respectively.

NOTE_11_SUBSEQUENT_EVENTS

NOTE 11 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
NOTE 11 - SUBSEQUENT EVENTS	'
	NOTE 11 – SUBSEQUENT EVENTS
	During October 2014, we entered into two promissory notes with two investors totaling $35,000. These notes are part of our debenture agreement that states interest at 10% and maturing in one year. In addition, the investors are granted warrants to purchase one share of stock for each dollar loaned. The warrants are three-year warrants, vest immediately and can be exercised for $1.00 per share. We calculated a discount on these warrants in the amount of $7,980 and will amortize this over the life of the note to interest expense.
	On October 27, 2014, an investor purchased 400,000 shares of our common stock along with 200,000 5-year warrants to purchase our common stock at $0.50 per share and they vest immediately for $200,000 cash.
	On November 3, 2014, we extended a note with Dr. Sobol, a board member. The original note was due on October 31, 2014 and had a convertible provision at $0.50 per share. The extension negotiated reduced the conversion price, extended the note until November 3, 2015 and we granted Dr. Sobol a 7-year warrant to purchase 15,000 shares of common stock at $0.20 per share. We calculated a gain on the extinguishment of the original debt in the amount of $3,435 and will recognize this gain during fourth quarter, 2014. In addition, we calculated a discount related to the beneficial conversion feature in the amount of $3,285 and will amortize this amount to interest expense over the life of the note. We also calculated a discount related to the granting of the warrants in the amount of $3,435 and this will be amortized to interest expense over the life of the note.

NOTE_2_SUMMARY_OF_SIGNIFICANT_1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of presentation and principles of consolidation	'
	Basis of presentation and principles of consolidation
	The accompanying consolidated unaudited interim financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC.
	All intercompany accounts have been eliminated for the purpose of the consolidated financial statement presentation.
Use of estimates	'
	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash	'
	Cash
	We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
Accounts receivable	'
	Accounts receivable
	Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We consider all accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $2,526 at both September 30, 2014 and 2013.
Inventory	'
	Inventory
	Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the first-in, first-out method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.
Property and equipment	'
	Property and equipment
	Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Office equipment		3 years
	Production equipment		5 to 7 years
	Equipment under capital lease		5 to 7 years
	Leasehold improvements		Lesser of lease term or useful life of improvement
Patents	'
	Patents
	Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	Our long-lived assets, which include property and equipment, patents, and licenses of patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. There was an impairment on patents recorded for the third quarter ended September 30, 2014, amounting to $27,080.
Discount on convertible notes payable	'
	Discount on convertible notes payable
	We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statements of operations.
Fair value of financial instruments	'
	Fair value of financial instruments
	The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable, approximate their fair values (determined based on level 1 inputs in the fair value hierarchy) because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
Fair value measurements	'
	Fair value measurements
	We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3		Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at September 30, 2014 or 2013, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the periods ended September 30, 2014 and September 30, 2013.
Revenue recognition	'
	Revenue recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.
	Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.
	Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2012 and 2011, we incurred $26,059 and $32,784, respectively, in shipping costs included in cost of goods sold.
Shipping and handling costs	'
	Shipping and handling costs
	Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2013 and 2012, we incurred $31,996 and $26,059, respectively, in shipping costs included in cost of goods sold.
Advertising and promotion costs	'
	Advertising and promotion costs
	Costs associated with the advertising and promotions of our products are expensed as incurred.
Equity instruments issued to parties other than employees for acquiring goods or services	'
	Equity instruments issued to parties other than employees for acquiring goods or services
	We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock.
	The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.
	The assumptions used to determine the fair value of our warrants are as follows:
	-	The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.
	-	The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant.
	-	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.
	-	The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.
Income taxes	'
	Income taxes
	We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.
	We did not record an income tax provision for the three months and nine months ended September 30, 2014 and 2013 as we had a net taxable loss in the periods.
Net loss per common share	'
	Net loss per common share
	Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for three months ended September 30, 2014 and 2013 and the nine months ended September 30, 2014 and 2013. The following table presents a reconciliation of basic loss per share and excluded dilutive securities:
				For the Three Months Ended September 30,		For the Nine Months Ended September 30,
				2014	2013	2014	2013
	Numerator:
	Net loss			($558,342)	($550,528)	($1,604,493)	($2,041,135)
	Denominator:
	Weighted-average common shares outstanding			10,091,052	7,712,950	8,986,310	7,395,137
	Basic and diluted net loss per share			($0.06)	($0.07)	($0.18)	($0.28)
	Common stock warrants			5,019,006	3,987,744	5,019,006	3,987,744
	Series A convertible preferred stock			2,078,070	2,699,690	2,078,070	2,699,690
	Stock options			2,848,670	1,651,118	2,848,670	1,651,118
	Convertible debt including interest			915,085	856,030	915,085	856,030
	Excluded dilutive securities			10,860,831	9,194,582	10,860,831	9,194,582
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segments	'
	Segments
	We have determined that we operate in one segment for financial reporting purposes.
Recently issued accounting pronouncements	'
	Recently issued accounting pronouncements
	In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements.

NOTE_2_SUMMARY_OF_SIGNIFICANT_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Estimated Useful Lives of the Assets	'
	Office equipment	3 years
	Production equipment	5 to 7 years
	Equipment under capital lease	5 to 7 years
	Leasehold improvements	Lesser of lease term or useful life of improvement
Net Loss Per Common Share	'
			For the Three Months Ended September 30,		For the Nine Months Ended September 30,
			2014	2013	2014	2013
	Numerator:
	Net loss		($558,342)	($550,528)	($1,604,493)	($2,041,135)
	Denominator:
	Weighted-average common shares outstanding		10,091,052	7,712,950	8,986,310	7,395,137
	Basic and diluted net loss per share		($0.06)	($0.07)	($0.18)	($0.28)
	Common stock warrants		5,019,006	3,987,744	5,019,006	3,987,744
	Series A convertible preferred stock		2,078,070	2,699,690	2,078,070	2,699,690
	Stock options		2,848,670	1,651,118	2,848,670	1,651,118
	Convertible debt including interest		915,085	856,030	915,085	856,030
	Excluded dilutive securities		10,860,831	9,194,582	10,860,831	9,194,582

NOTE_3_INVENTORY_Tables

NOTE 3 - INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
		September 30,	December 31,
		2014	2013
	Raw materials	$ 217,430	$ 240,750
	Finished goods	50,412	49,255
		267,842	290,005
	Less:  reserve for excess and obsolete inventory	-151,064	-151,064
		$ 116,778	$ 138,941

NOTE_4_PROPERTY_AND_EQUIPMENT_

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
		September 30,	December 31,
		2014	2013
	Office equipment	$ 27,507	$ 26,284
	Production equipment	86,999	83,615
	Leasehold improvements	16,328	16,328
		130,34	126,227
	Less:  accumulated depreciation	-82,251	-64,082
		$ 84,583	$ 62,145

NOTE_5_PATENTS_AND_LICENSES_NE1

NOTE 5 - PATENTS AND LICENSES, NET (Tables)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Patents and Licenses	'
		September 30,	December 31,
		2014	2013
	Licenses and amortizable patents	$ 207,244	$ 234,324
	Unamortized patents	153,630	125,301
	Accumulated amortization	-27,197	-16,127
	Patents and Licenses, net	$ 333,677	$ 343,498

NOTE_6_ACCRUED_EXPENSES_Tables

NOTE 6 - ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Accrued Expenses	'
		September 30,	December 31,
		2014	2013
	Executive compensation	$30,197	$476,368
	Other accruals	19,575	60,671
		$49,772	$537,039

NOTE_7_NOTES_PAYABLE_Tables

NOTE 7 - NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
		September 30,	December 31,
		2014	2013
	Notes payable - current
	7.85% unsecured, $781 due monthly	$3,659	$1,964
	7.85% unsecured, $373 due monthly	1,105	-
	4.15% unsecured, $2,678 due monthly	-	21,824
	10.00% unsecured, interest only, due December 30, 2014	25,000	-
		$29,764	$23,788
Short Term Convertible Notes Payable, Net	'
	Convertible notes payable, net	September 30,	31-Dec-13
		2014
	8%, unsecured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share.	$312,500	$263,496
	8% secured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share.	50,000	37,700
	6% unsecured, convertible into common stock at $2.00 per share, due on demand	50,000	50,000
	8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $40,552 in 2013), convertible into common stock at an average price of $0.205 per share  This note was converted during August 2014.	-	22,448
	8% unsecured due November 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after September 2, 2014.  This note was converted during August 2014.	-	-
	8% unsecured due January 2015 (net of discount related to beneficial conversion feature of $9,152 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after October 17, 2014.	23,348	-
	8% unsecured due March 2015 (net of discount related to beneficial conversion feature of $14,382 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after December 13, 2014.	18,118	-
	10% unsecured due March 2015 (net of discount related to warrants of $4,725 in 2014 and $0 in 2013) convertible price not yet determined	20,275	-
	10% unsecured due April 2015 (net of discount related to warrants of $19,600 in 2014 and $0 in 2013) convertible price not yet determined	80,400	-
	10% unsecured due April 2015 (net of discount related to warrants of $2,409 in 2014 and $0 in 2013) convertible price not yet determined	7,591	-
	8% unsecured due April 2015 (net of discount related to beneficial conversion feature of $22,227 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after January 14, 2015.	20,273	-
	8% unsecured due May 2015 (net of discount related to beneficial conversion feature of $31,983 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after February 11, 2015.	21,017	-
	10% unsecured due August 2015 (net of discount related to warrants of $6,600 in 2014 and $0 in 2013) convertible price not yet determined	23,400	-
	10% unsecured due September 2015 (net of discount related to warrants of $2,374 in 2014 and $0 in 2013) convertible price not yet determined	7,626	-
		$634,548	$373,644
Convertible notes payable, net related party	'
	Convertible notes payable, net related party	30-Sep-14	31-Dec-14
	0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share.  This note was paid off on March 31, 2014.	$ -	$23,427
	0% unsecured due October 1, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $0 in 2013 convertible into common stock at $0.50 per share.  Subsequent to September 30, 2014, we reached an agreement with the note holder to extend the maturity date.  See Note 11 for further details.	$15,000	$ -
		$15,000	$23,427

NOTE_9_STOCKHOLDERS_EQUITY_DEF1

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2014
Option Activity	'
					Weighted
					Average
				Weighted	Remaining
		Number of	Exercise Price	Average Exercise	Contractual Term	Aggregate Intrinsic
		Shares	Range	Price	(Years)	Value
	Outstanding, December 31, 2012	1,202,099	$ 0.40-$1.00	$0.56	7.74	-
	Exercisable, December 31, 2012	830,504	$ 0.40-$1.00	$0.57	8.19	-
	Granted	1,150,000	$ 0.38-$0.81	$0.47	8.07	-
	Exercised	-	-	$ -	-	-
	Expired	-	-	$ -	-	-
	Outstanding, December 31, 2013	2,352,099	$ 0.38-$1.00	$0.51	7.9	199,505
	Exercisable, December 31, 2013	1,810,344	$ 0.38-$1.00	$0.52	7.88	138,707
	Granted	496,571	$ 0.40-$0.75	$0.48	6.36
	Exercised	-	-	$ -	-
	Expired	-	-	$ -	-
	Outstanding, September 30, 2014	2,848,670	$ 0.38-$1.00	$0.52	7.68	-
	Exercisable, September 30, 2014	2,125,502	$ 0.38-$1.00	$0.49	9.13	-
Range of Options Exercise Price	'
	Number of	Exercise
	shares	Price
	55,000	$0.38
	1,286,670	$0.40
	30,000	$0.42
	20,000	$0.44
	190,000	$0.45
	824,000	$0.50
	160,000	$0.60
	15,000	$0.62
	20,000	$0.75
	10,000	$0.81
	200,000	$0.85
	38,000	$1.00
	2,848,670
Outstanding Warrants	'
	Date of Issue	30-Sep-14	Exercise Price	Expiration
	14-Sep	316,208	$0.00	Sep-24
	14-Aug	80,000	$0.50 - $1.00	8/2017 - 8/2019
	14-Jun	15,000	$0.50	Jun-19
	14-Apr	113,333	$0.65 - 1.00	04/2017 - 03/2021
	14-Jan	62,277	$0.65 - $1.00	01/2019 - 01/2021
	As of December	4,457,188	$0.36 - $10.00	10/2014 - 10/2021
	2013
	Total	5,044,006
	Less:
	Expired	25,000
	Exercised	-
	Total	5,019,006
Option Member	'
Black-Scholes Option-Pricing Model Assumptions	'
		September 30,	December 31,
		2014	2013
	Expected dividend yield	-	-
	Expected stock price volatility	182.94%-216.96%	216.96% - 236.55%
	Risk-free interest rate	0.28% - 1.91%	0.95% - 2.47%
	Expected term (in years)	3 - 7 years	5 - 10 years
	Weighted-average granted date fair value	$0.48	$0.45
Warrant Member	'
Black-Scholes Option-Pricing Model Assumptions	'
		30-Sep-14	31-Dec-13
	Risk-Free interest rate	0.28% - 2.97%	0.95% - 3.32%
	Expected dividend yield	0%	0%
	Volatility	182.81%-222.30%	216.48%-239.20%
	Expected life	3 - 7 years	3-10 years

NOTE_1_ORGANIZATION_AND_OPERAT1

NOTE 1 - ORGANIZATION AND OPERATIONS (Details Narrative) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'	'	'	'	'
Cash and cash equivalents	$85,608	$36,886	$45,355	$13,161	$33,409	$13,081

NOTE_2_ESTIMATED_USEFUL_LIVES_

NOTE 2 - ESTIMATED USEFUL LIVES OF THE ASSETS (Details)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Estimated useful life of office equipment	'3 years
Minimum estimated useful life of production equipment	'5 years
Maximum estimated useful life of production equipment	'7 years
Minimum estimated useful life of equipment under capital lease	'5 years
Maximum estimated useful life of equipment under capital lease	'7 years

NOTE_2_SUMMARY_OF_SIGNIFICANT_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER COMMON SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Reconciliation Of Basic Loss Per Share And Excluded Dilutive Securities	'	'	'	'
Numerator: Net loss applicable to common shareholders	($558,342)	($550,528)	($1,604,493)	($2,041,135)
Denominator: Weighted-average common shares outstanding	10,091,052	7,712,950	8,986,310	7,395,137
Basic and diluted net loss per share	($0.06)	($0.07)	($0.18)	($0.28)
Common stock warrants	5,019,006	3,987,744	5,019,006	3,987,744
Series A convertible preferred stock	2,078,070	2,699,690	2,078,070	2,699,960
Stock options	2,848,670	1,651,118	2,848,670	1,651,118
Convertible debt including interest	915,085	856,030	915,085	856,030
Excluded dilutive securities	10,860,831	9,194,582	10,860,831	9,194,582

NOTE_2_SUMMARY_OF_SIGNIFICANT_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes to Financial Statements	'	'
Allowance for doubtful accounts	$2,526	$2,526
Accounts receivable past due period	'30 days	'
Domestic patent life minimum (in years)	'15 years	'
Domestic patent life maximum (in years)	'20 years	'
Foreign patent life minimum (in years)	'5 years	'
Foreign patent life maximum (in years)	'20 years	'
Impairment of intangible asset	$27,080	'

NOTE_3_INVENTORY_Details

NOTE 3 - INVENTORY (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory	'	'
Raw materials	$217,430	$240,750
Finished goods	50,412	49,255
Inventory gross	267,842	290,005
Less: reserve for excess and obsolete inventory	-151,064	-151,064
Inventory net	$116,778	$138,941

NOTE_4_PROPERTY_AND_EQUIPMENT_1

NOTE 4 - PROPERTY AND EQUIPMENT - PROPERTY AND EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and Equipment	'	'
Office equipment	$27,507	$26,284
Production equipment	86,999	83,615
Leasehold improvements	16,328	16,328
Property and Equipment Gross	130,834	126,227
Less: accumulated depreciation	-82,251	-64,082
Property and Equipment Net	$48,583	$62,145

NOTE_5_PATENTS_AND_LICENSES_NE2

NOTE 5 - PATENTS AND LICENSES, NET - PATENTS AND LICENSES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Long-Lived Intangible Assets	'	'
Licenses and amortizable patents	$207,244	$234,324
Unamortized patents	153,630	125,301
Accumulated amortization	-27,197	-16,127
Patents and Licenses, net	$333,677	$343,498

NOTE_5_PATENTS_AND_LICENSES_NE3

NOTE 5 - PATENTS AND LICENSES, NET (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Notes to Financial Statements	'	'	'	'	'
Patent and license amortization	$3,371	$3,578	$11,070	$6,824	'
Amortization of licenses over economic useful life, maximum	'	'	'17 years	'	'
Impairment of intangible asset	27,080	0	27,080	0	'
License acquired for stock, fair value	'	'	'	'	$215,529

NOTE_6_ACCRUED_EXPENSES_Detail

NOTE 6 - ACCRUED EXPENSES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Notes to Financial Statements	'	'
Executive compensation	$30,197	$476,368
Other accruals	19,575	60,671
Total accrued expenses	$49,772	$537,039

NOTE_6_ACCRUED_EXPENSES_Detail1

NOTE 6 - ACCRUED EXPENSES (Details Narrative) (USD $)	3 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Stock issued to employees for accrued compensation conversion, shares	2,592,570
Accrued compensation converted to common stock and warrants, amount	$777,770
Stock issued to employees for accrued compensation conversion, price per share	$0.30
Warrants issued to employees for accrued compensation conversion	306,208
Exercise price of warrants issued to employeesd for accrued compensation conversion	$0.00
Fair Value of warrants issued to employeesd for accrued compensation conversion	$91,863
Length of warrant exercise duration	'10 years

NOTE_7_NOTES_PAYABLE_Details

NOTE 7 - NOTES PAYABLE (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Notes payable - current, 7.85% unsecured, $781 due monthly	'	'
Notes payable	$3,659	$1,964
Notes payable - current, 4.15% unsecured, $2,678 due monthly	'	'
Notes payable	1,105	0
Notes payable - current, 4.15% unsecured, $2,771 due monthly	'	'
Notes payable	0	21,824
Notes payable - current, 10.00% unsecured, interest only, due December 30, 2014	'	'
Notes payable	25,000	0
Notes Payable Current Total	'	'
Notes payable	29,764	23,788
Convertible Notes payable, net - 8%, unsecured note due June 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share	'	'
Notes payable	312,500	263,496
8% secured due August 2014 (net of discount related to beneficial conversion feature of $8,200 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share	'	'
Notes payable	50,000	37,700
6% unsecured, convertible into common stock at $2.00 per share, due March 31, 2014	'	'
Notes payable	50,000	50,000
Convertible Notes payable related party, net - 8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $25,345 in 2014 and $40,552 in 2013), convertible into common stock at a price to be determined after June 5, 2014	'	'
Notes payable	0	22,448
Notes payable - current, 8% unsecured due November 2014 (net of discount related to beneficial conversion feature of $23,655 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after September 2, 2014.	'	'
Notes payable	0	0
8% unsecured due January 2015 (net of discount related to beneficial conversion feature of $16,997 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after October 17, 2014.	'	'
Notes payable	23,348	0
8% unsecured due March 2015 (net of discount related to beneficial conversion feature of $22,227 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after December 13, 2014.	'	'
Notes payable	18,118	0
10% unsecured due March 2015 (net of discount related to warrants of $7,087 in 2014 and $0 in 2013) convertible price not yet determined	'	'
Notes payable	20,273	0
10% unsecured due April 2015 (net of discount related to warrants of $29,400 in 2014 and $0 in 2013) convertible price not yet determined	'	'
Notes payable	80,400	0
10% unsecured due April 2015 (net of discount related to warrants of $3,442 in 2014 and $0 in 2013) convertible price not yet determined	'	'
Notes payable	7,591	0
Convertible Notes Payable Current Total	'	'
Notes payable	634,548	373,644
0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share. This note was paid off on March 31, 2014.	'	'
Notes payable	0	23,427
Related Party Long Term Convertible Notes Payable Current Total	'	'
Notes payable	$15,000	$23,427

NOTE_7_NOTES_PAYABLE_Details_P

NOTE 7 - NOTES PAYABLE (Details) (Parenthetical) (USD $)

Jul. 14, 2014

Jul. 01, 2014

Sep. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Notes payable - current, 7.85% unsecured, $781 due monthly

Notes payable - current, 7.85% unsecured, $781 due monthly

Notes payable - current, 7.85% unsecured, $737 due monthly

Notes payable - current, 7.85% unsecured, $737 due monthly

Notes payable - current, 4.15% unsecured, $2,678 due monthly

Notes payable - current, 4.15% unsecured, $2,678 due monthly

Notes payable - current, 10.00% unsecured, interest only, due December 30, 2014

Notes payable - current, 10.00% unsecured, interest only, due December 30, 2014

Convertible Notes payable, net - 8%, unsecured note due June 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share

Convertible Notes payable, net - 8%, unsecured note due June 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share

8% secured due August 2014 (net of discount related to beneficial conversion feature of $8,200 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share

8% secured due August 2014 (net of discount related to beneficial conversion feature of $8,200 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share

6% unsecured, convertible into common stock at $2.00 per share, due March 31, 2014

6% unsecured, convertible into common stock at $2.00 per share, due March 31, 2014

Convertible Notes payable related party, net - 8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $25,345 in 2014 and $40,552 in 2013), convertible into common stock at a price to be determined after June 5, 2014

Convertible Notes payable related party, net - 8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $25,345 in 2014 and $40,552 in 2013), convertible into common stock at a price to be determined after June 5, 2014

Notes payable - current, 8% unsecured due November 2014 (net of discount related to beneficial conversion feature of $23,655 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after September 2, 2014.

Notes payable - current, 8% unsecured due November 2014 (net of discount related to beneficial conversion feature of $23,655 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after September 2, 2014.

0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share. This note was paid off on March 31, 2014.

0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share. This note was paid off on March 31, 2014.

8% unsecured due January 2015 (net of discount related to beneficial conversion feature of $16,997 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after October 17, 2014.

8% unsecured due January 2015 (net of discount related to beneficial conversion feature of $16,997 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after October 17, 2014.

8% unsecured due March 2015 (net of discount related to beneficial conversion feature of $22,227 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after December 13, 2014.

8% unsecured due March 2015 (net of discount related to beneficial conversion feature of $22,227 in 2014 and $0 in 2013), convertible into common stock at a price to be determined after December 13, 2014.

10% unsecured due March 2015 (net of discount related to warrants of $7,087 in 2014 and $0 in 2013) convertible price not yet determined

10% unsecured due March 2015 (net of discount related to warrants of $7,087 in 2014 and $0 in 2013) convertible price not yet determined

10% unsecured due April 2015 (net of discount related to warrants of $29,400 in 2014 and $0 in 2013) convertible price not yet determined

10% unsecured due April 2015 (net of discount related to warrants of $29,400 in 2014 and $0 in 2013) convertible price not yet determined

10% unsecured due April 2015 (net of discount related to warrants of $3,442 in 2014 and $0 in 2013) convertible price not yet determined

10% unsecured due April 2015 (net of discount related to warrants of $3,442 in 2014 and $0 in 2013) convertible price not yet determined

Monthly due on note payable

'

'

$781

$781

$373

$373

$2,678

$2,678

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount related to beneficial conversion feature

$30,776

$7,545

'

'

'

'

'

'

'

'

$0

$49,004

$0

$12,300

'

'

$0

$40,552

$23,655

$0

$0

$16,573

$9,152

$0

$14,382

$0

$4,725

$0

$19,600

$0

$2,409

$0

Convertible to preferred stock, price per share

'

'

'

'

'

'

'

'

'

'

'

'

$5

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible to common stock, price per share

'

'

'

'

'

'

'

'

'

'

$0.45

$0.45

'

'

$2

$2

'

'

'

'

$0.65

$0.65

'

'

'

'

'

'

'

'

'

'

Interest percent of note payable

'

'

7.85%

7.85%

7.85%

7.85%

4.15%

4.15%

10.00%

10.00%

8.00%

8.00%

8.00%

8.00%

'

'

8.00%

8.00%

8.00%

8.00%

'

'

8.00%

8.00%

8.00%

8.00%

10.00%

10.00%

10.00%

10.00%

10.00%

10.00%

NOTE_7_NOTES_PAYABLE_Details_N

NOTE 7 - NOTES PAYABLE (Details Narrative) (USD $)

1 Months Ended

3 Months Ended

Jul. 31, 2014

Apr. 30, 2014

Sep. 30, 2014

Jul. 14, 2014

Jul. 01, 2014

Jun. 13, 2014

Apr. 27, 2014

Apr. 17, 2014

Apr. 15, 2014

Mar. 25, 2014

Feb. 03, 2014

Dec. 31, 2013

Notes to Financial Statements

'

'

'

'

'

'

'

'

'

'

'

'

Promissory note amount, instant

'

'

'

'

'

'

$25,000

'

$100,000

$10,000

'

'

Promissory note term in months, duration

'

'

'12 months

'

'

'

'

'

'

'

'

'

Interest rate of promissory note, instant

'

'

'

'

'

'

10.00%

'

10.00%

10.00%

'

'

Line of credit arrangement amount

'

'

'

'

'

'

'

'

'

60,000

'

'

Interest rate of line of credit on top of prime

'

'

'

'

'

'

'

'

'

3.00%

'

'

Line of credit amount oustanding

'

'

'

'

'

'

'

'

'

11,750

'

'

Amount of note payable due on June 30, 2014

'

'

312,500

'

'

'

'

'

'

'

'

'

Fair value of warrants granted to note holder

'

'

'

'

'

'

39,200

'

4,130

9,450

'

'

Convertible price, per share

'

'

'

'

$0.50

'

'

'

'

'

'

'

Discount for the beneficial conversion feature of the convertible promisorry note

'

'

'

30,776

7,545

'

'

'

'

'

'

'

Convertible promissory note amount, instant

'

'

634,548

42,500

15,000

32,500

'

32,500

'

'

42,000

373,644

Convertible promissory note term in months, duration

'4 months

'

'

'

'

'

'

'

'

'

'

'

Due date of convertible promissory note

'

'

'6 months

'

'

'

'

'

'

'

'

'

Interest rate of convertible promissory note, instant

'

'

'

8.00%

'

8.00%

'

8.00%

'

'

8.00%

'

Convertible price, per share, instant

'

'

'

'

$0.50

'

'

'

'

'

'

'

Convertible price, percent of market trading price

'

'

'

'

'

58.00%

'

58.00%

'

'

58.00%

'

Period until Convertible note is convertible

'180 days

'

'

'

'

'

'

'

'

'

'

'

Discount for the beneficial conversion feature of the convertible promisorry note, instant

'

'

'

30,776

7,545

'

'

'

'

'

'

'

Discount for the beneficial conversion feature of the convertible promisorry note, duration

'

'

77,482

'

'

'

'

'

'

'

'

'

Warrants granted for promissory note issuance

15,000

110,000

110,000

'

'

'

'

'

'

'

'

'

Warrant term, in years

'5 years

'3 years

'3 years

'

'

'

'

'

'

'

'

'

Warrant exercise price per share

$0.50

$1

$1

'

'

'

'

'

'

'

'

'

Discount on granting warrants

'

'

52,780

'

'

'

'

'

'

'

'

'

Beneficial conversion feature amortized in 2014

'

'

14,603

'

'

'

'

'

'

'

'

'

Debt converted to common stock, value

$33,000

'

'

'

'

'

'

'

'

'

'

'

Debt converted to common stock, shares

226,530

'

'

'

'

'

'

'

'

'

'

'

NOTE_8_RELATED_PARTY_TRANSACTI1

NOTE 8 - RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	1 Months Ended			3 Months Ended
	Jul. 31, 2014	Apr. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Jul. 14, 2014	Jul. 01, 2014	Jun. 13, 2014	Apr. 17, 2014	Feb. 03, 2014
Notes to Financial Statements	'	'	'	'	'	'	'	'	'
Promissory note due to affiliate, amount, duration	'	'	$40,000	'	'	'	'	'	'
Promissory note due to affiliate, interest percent, duration	'	'	0.00%	'	'	'	'	'	'
Promissory note due to affiliate, paid in full date	'	'	31-Mar-14	'	'	'	'	'	'
Convertible promissory note amount, instant	'	'	373,644	634,548	42,500	15,000	32,500	32,500	42,000
Convertible promissory note term in months, duration	'4 months	'	'	'	'	'	'	'	'
Due date of convertible promissory note	'2015-04-01	'	'	'	'	'	'	'	'
Interest rate of convertible promissory note, instant	'	'	'	'	8.00%	'	8.00%	8.00%	8.00%
Convertible price, per share, instant	'	'	'	'	'	$0.50	'	'	'
Convertible price, percent of market trading price	'	'	'	'	'	'	58.00%	58.00%	58.00%
Period until Convertible note is convertible	'180 days	'	'	'	'	'	'	'	'
Discount for the beneficial conversion feature of the convertible promisorry note, instant	'	'	'	'	30,776	7,545	'	'	'
Discount for the beneficial conversion feature of the convertible promisorry note, duration	'	'	'	77,482	'	'	'	'	'
Warrants granted for promissory note issuance	15,000	110,000	'	110,000	'	'	'	'	'
Warrant term, in years	'5 years	'3 years	'	'3 years	'	'	'	'	'
Warrant exercise price per share	$0.50	$1	'	$1	'	'	'	'	'
Discount on granting warrants	'	'	'	'	'	$5,445	'	'	'

NOTE_9_STOCKHOLDERS_EQUITY_DEF2

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) - BLACK-SCHOLES OPTION-PRICING MODEL ASSUMPTIONS (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2012
Option Member	'	'
Risk-Free interest rate, minimum	0.28%	0.95%
Risk-Free interest rate, maximum	191.00%	2.47%
Expected dividend yield	0.00%	0.00%
Expected stock price volatility, minimum	182.94%	216.96%
Expected stock price volatility, maximum	216.96%	236.55%
Expected term (in years), minimum	'3 years	'5 years
Expected term (in years), maximum	'7 years	'10 years
Weighted-average granted date fair value	$0.48	$0.45
Warrant Member	'	'
Risk-Free interest rate, minimum	0.28%	0.95%
Risk-Free interest rate, maximum	2.97%	3.32%
Expected dividend yield	0.00%	0.00%
Expected stock price volatility, minimum	182.81%	21648.00%
Expected stock price volatility, maximum	222.30%	23920.00%
Expected term (in years), minimum	'3 years	'5 years
Expected term (in years), maximum	'7 years	'10 years
Weighted-average granted date fair value	$0.75	$0.45

NOTE_9_OPTION_ACTIVITY_Details

NOTE 9 - OPTION ACTIVITY (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Exercisable	'	'	'
Number of Shares, instant	2,125,502	1,810,344	830,504
Exercise Price Range, instant, minimum	$0.38	$0.38	$0.40
Exercise Price Range, instant, maximum	$1	$1	$1
Weighted Average Exercise Price, instant	$0.49	$0.52	$0.57
Weighted Average Remaining Contractual Life (in years), duration	'9 years 2 months	'7 years 10 months	'
Aggregate Intrinsic Value, instant	'	$138,707	$0
Outstanding	'	'	'
Number of Shares, instant	2,848,670	2,352,099	1,202,099
Exercise Price Range, instant, minimum	$0.38	$0.38	$0.40
Exercise Price Range, instant, maximum	$1	$1	$1
Weighted Average Exercise Price, instant	$0.52	$0.51	$0.56
Weighted Average Remaining Contractual Life (in years), duration	'7 years 8 months	'7 years 10 months	'
Aggregate Intrinsic Value, instant	'	199,505	0
Granted	'	'	'
Number of Shares, duration	496,571	1,150,000	'
Exercise Price Range, duration, minimum	$0.40	$0.38	'
Exercise Price Range, duration, maximum	$0.75	$0.81	'
Weighted Average Exercise Price, duration	$0.48	$0.47	'
Weighted Average Remaining Contractual Life (in years), duration	'6 years 5 months	'8 years 1 month	'
Aggregate Intrinsic Value, duration	0	0	'
Exercised	'	'	'
Number of Shares, duration	0	0	'
Exercise Price Range, duration, minimum	$0	$0	'
Exercise Price Range, duration, maximum	$0	$0	'
Weighted Average Exercise Price, duration	$0	$0	'
Weighted Average Remaining Contractual Life (in years), duration	'0 years	'0 years	'
Aggregate Intrinsic Value, duration	0	0	'
Expired	'	'	'
Number of Shares, duration	0	0	'
Exercise Price Range, duration, minimum	$0	$0	'
Exercise Price Range, duration, maximum	$0	$0	'
Weighted Average Exercise Price, duration	$0	$0	'
Weighted Average Remaining Contractual Life (in years), duration	'0 years	'0 years	'
Aggregate Intrinsic Value, duration	$0	$0	'

NOTE_9_RANGE_OF_OPTIONS_EXERCI

NOTE 9 - RANGE OF OPTIONS EXERCISE PRICE (Details)	Sep. 30, 2014
Total number of option shares outstanding	2,848,670
Options $0.38	'
Number of Shares underlying options	55,000
Options $0.40	'
Number of Shares underlying options	1,286,670
Options $0.44	'
Number of Shares underlying options	20,000
Options $0.45	'
Number of Shares underlying options	30,000
Options $0.47	'
Number of Shares underlying options	247,242
Options $0.49	'
Number of Shares underlying options	190,000
Options $0.50	'
Number of Shares underlying options	824,000
Options $0.62	'
Number of Shares underlying options	160,000
Options $0.65	'
Number of Shares underlying options	15,000
Options $0.75	'
Number of Shares underlying options	20,000
Options $0.60	'
Number of Shares underlying options	160,000
Options $0.81	'
Number of Shares underlying options	10,000
Options $0.85	'
Number of Shares underlying options	200,000
Options $1.00	'
Number of Shares underlying options	38,000

NOTE_9_OUTSTANDING_WARRANTS_De

NOTE 9 - OUTSTANDING WARRANTS (Details) (USD $)	9 Months Ended	12 Months Ended	1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Apr. 30, 2014	Jan. 28, 2014
			Issued Warrants	Issued Warrants	Issued Warrants
Warrants issued, shares	'	'	15,000	113,333	62,277
Exercise price, per share, minimum	'	'	$0.50	$0.65	$0.65
Exercise price, per share, maximum	'	'	$0.50	$1	$1
Exercise price, per share, minimum, instant	'	$0.36	'	'	'
Exercise price, per share, maximum, instant	'	$10	'	'	'
Expiration date, earliest	'	'2013-10	'2019-06	'2017-04	'2019-01
Expiration date, latest	'	'2021-10	'2019-06	'2012-03	'2021-01
Warrants outstanding	5,019,006	4,457,188	'	'	'
Expired warrants	25,000	'	'	'	'

NOTE_9_STOCKHOLDERS_EQUITY_DEF3

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012	26-May-11
Preferred Stock	'	'	'	'	'	'
Shares of preferred stock designated as Series A preferred stock	'	'	'	'	'	350,000
Series A preferred stock par value	'	'	'	'	'	$0.00
Liquidation preference per Series A preferred share	'	'	'	'	'	$5
Basis that Series A Preferred stock is convertible into common stock	'	'	'1:10	'	'	'
Series A preferred shares converted to common stock	44,162	'	'	'	'	'
Common stock issued for conversion of Series A preferred shares	441,620	'	'	'	'	'
Common Stock	'	'	'	'	'	'
Common stock issued upon conversion of convertible notes payable, shares	151,126	'	'	'	'	'
Common stock issued upon conversion of convertible notes payable, value	$32,520	'	'	'	'	'
Convertible notes payable converted to common stock	30,000	'	'	'	'	'
Common stock issued upon conversion of convertible notes payable, interest accrued	2,520	'	'	'	'	'
Stock issued for services, value	13,113	39,556	107,882	'	'	'
Stock issued for services, shares	23,000	64,700	'	'	'	'
Common stock issued for future services, value	'	44,250	'	'	'	'
Common stock issued for future services, shares	'	68,283	'	'	'	'
Stock issued for accounts payable, value	46,400	4,501	55,901	0	'	'
Stock issued for accounts payable, shares	80,000	6,717	'	'	'	'
Stock issued for accounts payable, amound owed	149,421	'	'	'	'	'
Gain on settlement of shares issued for accounts payable	103,021	'	'	'	'	'
Stock incentive plan	'	'	'	'	'	'
Common shares reserved for the 2010 Stock Incentive Plan	4,650,000	'	4,650,000	'	'	'
Annual increase in reserved shares of the 2010 Stock Incentive Plan	'	'	'	'	50,000	'
Unissued option shares available under the Plan	2,077,901	'	2,077,901	'	'	'
Total unrecognized compensation cost related to unvested stock options	$263,507	'	$263,507	'	'	'

NOTE_10_COMMITMENTS_AND_CONTIN1

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	8 Months Ended	12 Months Ended		14 Months Ended
	31-May-14	Sep. 30, 2013	Dec. 31, 2012	Jul. 31, 2015	Sep. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Jun. 01, 2012
								sqft
Notes to Financial Statements	'	'	'	'	'	'	'	'
Square feet of leased office and warehouse space	'	'	'	'	'	'	'	13,081
Monthly rental rate of office space	$3,260	$3,160	'	$3,343	'	'	'	'
Period of office lease	'	'	'3 years	'	'	'	'	'
Deferred rent accrual	'	'	'	'	$4,160	$6,555	$15,585	'

NOTE_11_SUBSEQUENT_EVENTS_Deta

NOTE 11 - SUBSEQUENT EVENTS (Details Narrative) (USD $)	1 Months Ended		3 Months Ended
	Jul. 31, 2014	Apr. 30, 2014	Sep. 30, 2014	Jul. 14, 2014	Jul. 01, 2014	Jun. 13, 2014	Apr. 17, 2014	Feb. 03, 2014	Dec. 31, 2013
Subsequent Events [Abstract]	'	'	'	'	'	'	'	'	'
Series A preferred shares converted to common stock	'	'	44,162	'	'	'	'	'	'
Common stock issued for conversion of Series A preferred shares	'	'	441,620	'	'	'	'	'	'
License fee incurred	'	'	'	'	'	'	'	'	$140,000
Outstanding royalties owed on license fee	'	'	'	'	'	'	'	'	3,108
Common stock issued in exchange for license fee debt	'	'	'	'	'	'	'	'	80,000
Common stock issued in exchange for license fee debt, value	'	'	'	'	'	'	'	'	51,200
Gain on extinguishment of accounts payable	'	'	91,908	'	'	'	'	'	'
Convertible promissory note amount, instant	'	'	634,548	42,500	15,000	32,500	32,500	42,000	373,644
Convertible promissory note term in months, duration	'4 months	'	'	'	'	'	'	'	'
Due date of convertible promissory note	'2015-04-01	'	'	'	'	'	'	'	'
Interest rate of convertible promissory note, instant	'	'	'	8.00%	'	8.00%	8.00%	8.00%	'
Convertible price, per share, instant	'	'	'	'	$0.50	'	'	'	'
Convertible price, percent of market trading price	'	'	'	'	'	58.00%	58.00%	58.00%	'
Period until Convertible note is convertible	'180 days	'	'	'	'	'	'	'	'
Discount for the beneficial conversion feature of the convertible promisorry note, instant	'	'	'	30,776	7,545	'	'	'	'
Discount for the beneficial conversion feature of the convertible promisorry note, duration	'	'	77,482	'	'	'	'	'	'
Warrants granted for promissory note issuance	15,000	110,000	110,000	'	'	'	'	'	'
Warrant term, in years	'5 years	'3 years	'3 years	'	'	'	'	'	'
Warrant exercise price per share	$0.50	$1	$1	'	'	'	'	'	'
Discount on granting warrants	'	'	'	'	5,445	'	'	'	'
Debt converted to common stock, value	$33,000	'	'	'	'	'	'	'	'
Debt converted to common stock, shares	226,530	'	'	'	'	'	'	'	'